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Translational repression of pre-formed cytokineencoding mRNA prevents chronic activation of
memory T cells
Fiamma Salerno1, Sander Engels1, Maartje van den Biggelaar2, Floris P. J. van Alphen2,
Aurelie Guislain1, Wanqi Zhao1, Deborah L. Hodge3, Sarah E. Bell 4, Jan Paul Medema5,
Marieke von Lindern1, Martin Turner 4, Howard A. Young3 and Monika C. Wolkers 1*
Memory T cells are critical for the immune response to recurring infections. Their instantaneous reactivity to pathogens is
empowered by the persistent expression of cytokine-encoding mRNAs. How the translation of proteins from pre-formed cytokine-encoding mRNAs is prevented in the absence of infection has remained unclear. Here we found that protein production in
memory T cells was blocked via a 3′untranslated region (3′UTR)-mediated process. Germline deletion of AU-rich elements
(AREs) in the Ifng-3′UTR led to chronic cytokine production in memory T cells. This aberrant protein production did not result
from increased expression and/or half-life of the mRNA. Instead, AREs blocked the recruitment of cytokine-encoding mRNA to
ribosomes; this block depended on the ARE-binding protein ZFP36L2. Thus, AREs mediate repression of translation in mouse
and human memory T cells by preventing undesirable protein production from pre-formed cytokine-encoding mRNAs in the
absence of infection.

M

emory T cells (TM cells) are critical for the immune
response against recurring infections. Their longevity and
tissue localization allows TM cells to maintain effective
immunity against bacteria, protozoa and viruses1–3. A key characteristic of both CD8+ and CD4+ TM cells is their capacity to produce
substantial amounts of effector molecules within a few hours upon
reinfection4–6. This rapid responsiveness limits pathogen spread
and recruits innate immune cells to the site of infection7,8. The swift
recall response by TM cells is supported by changes in chromatin
structure and epigenetic modifications that increase transcription
rates of genes encoding effector molecules9–11. As a result, mRNAs
encoding proinflammatory cytokines such as interferon (IFN)-γ
are higher in human and mouse TM cells than in naive T cells12–14.
Pre-formed Ifng and tumor necrosis factor (Tnf) mRNA is critical for instantaneous protein production upon T cell activation15.
Such pre-formed mRNA is advantageous for recall responses, as
cytokines can be rapidly produced without initiating transcription.
However, chronic cytokine production can elicit severe immunopathology16,17. Because pre-formed mRNA is ready to be translated, it is critical that protein production is tightly regulated and
strictly confined to reactivated TM cells. How chronic and undesired
cytokine production from pre-formed mRNA is prevented in TM
cells is unknown.
Post-transcriptional regulation is a critical modulator of protein
production, acting by regulating mRNA stability, changing mRNA
localization and inhibiting protein translation. RNA-binding proteins (RBPs) and noncoding RNAs such as microRNAs mediate
these processes by binding to sequences located in the 3′UTR of
the mRNA18–20. For instance, global downregulation of microRNAs

during T cell activation promotes the acquisition of effector functions21,22. Whereas microRNA activity is primarily associated with
keeping T cells quiescent, RBPs can directly promote T cell effector responses. The activity of RBPs can be regulated by different
post-translational modifications23,24. RBPs bind to secondary RNA
structures, such as the constitutive decay element25, or to short
single-stranded sequences, such as GU-rich or AU-rich elements
(AREs)26. The 3′UTR of many cytokines, including Ifng, Tnf and
interleukin-2 (Il2), contain AREs that consist of one or several
AUUUA pentamers27. RBP binding to AREs is thought to primarily
modulate mRNA stability, which is supported by the observation
that many ARE-bearing transcripts display a short mRNA half-life28.
We found here that rapid mRNA turnover was not sufficient to
avoid chronic protein production in TM cells. Rather, AREs were
critical for blocking translation of pre-formed mRNA, a process that
was mediated by the ARE-binding protein ZFP36L2. Thus, TM cells
can contain deployment-ready mRNA for rapid recall responses
because the recruitment of pre-formed cytokine mRNA to ribosomes is prevented in the absence of infection.

Results

The 3′ UTR of Ifng determines protein expression levels in
TM cells. We first examined whether the Ifng 3′UTR regulated
protein production in TM cells. We fused the mouse Ifng 3′ UTR
to a GFP reporter gene (hereafter GFP-Ifng3′UTR) under the control of the mouse Pgk1 promoter. We retrovirally transduced OTI
T cell antigen receptor (TCR) transgenic CD8+ T cells expressing
the congenic marker CD45.1 with GFP-Ifng3′UTR or with GFP that
lacked a 3′UTR (hereafter GFPcontrol). The next day, 1,000 sorted
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Fig. 1 | The 3′ UTR of Ifng governs GFP expression in memory T cells in vivo. a, Blood samples of LM-OVA-infected C57BL/6 J/CD45.2 recipient mice
were analyzed for the presence of CD45.1+ OTI cells expressing GFP-Ifng3′UTR or GFPcontrol reporter (n =10 per group; mean ± s.d.). b,c, GFP MFI levels
measured directly ex vivo in spleen-residing (b) and liver-residing (c) OTI cells 35 d after infection (unpaired Student t-test; n =5 mice per group;
mean ± s.d.; **P <0.005), showing representative GFP expression in memory OTI cells directly ex vivo (memory) and upon reactivation with OVA257–264
peptide (+OVA (6 h)). Numbers in plots depict the GFP MFI of the total population (top number) and the percentage of T cells within the upper gate that
express high GFP levels (bottom number). Data shown are representative of 2 independently performed experiments.

GFP-Ifng3′UTR OTI or GFPcontrol OTI cells were transferred into
naive C57BL/6J/CD45.2 recipient mice, followed by infection with
the intracellular bacterium Listeria monocytogenes genetically engineered to express ovalbumin (LM-OVA)29 the next day. We found
identical percentages of GFP-Ifng3′UTR and GFPcontrol OTI cells in
the blood of recipient mice at all time points measured (Fig. 1a).
The GFPcontrol OTI cells expressed constant levels of GFP throughout
the infection as determined by the GFP mean fluorescence intensity
(GFP MFI; Supplementary Fig. 1a). In contrast, the GFP MFI in GFPIfng3′UTR OTI cells increased at day 9 postinfection and dropped
at day 13, when the infection was resolved (Supplementary Fig. 1a).
At day 35 postinfection, the GFP MFI was about sixfold lower
for GFP-Ifng3′UTR OTI cells than for GFPcontrol OTI cells isolated
from blood, liver and spleen (Fig. 1b,c and Supplementary Fig. 1b).
Reactivation of OTI cells isolated at day 35 postinfection with
the OVA257–264 peptide did not alter the MFI of GFPcontrol OTI cells
(P = 0.4), but it increased the expression of GFP-Ifng3′UTR compared to nonactivated cells (P =  0.01, Fig. 1b,c).
Spleen-derived GFPcontrol CD4+ and CD8+ T cells from C57BL/6J
mice showed high GFP MFI when cultured in interleukin-7 for several days in the absence of antigen (hereafter ‘resting’), and reactivation for 4 h with phorbol 12-myristate 13-acetate (PMA) plus
ionomycin did not alter the GFP MFI. In contrast, GFP-Ifng3′UTR
T cells had low GFP MFI when resting, and reactivation led to GFP
induction (Supplementary Fig. 1c–f). The MFI of endogenous IFN-γ
protein was equal in GFP+ and GFP– T cells (Supplementary Fig. 1g),
indicating that the factors that control protein production were not
limiting. Similar results were obtained using the minimal mouse
Ifng promoter30 (Supplementary Fig. 1h), suggesting that the regulatory capacity of the Ifng 3′UTR is independent of a specific promoter. Combined, these data imply that the Ifng 3′UTR controls
protein production in TM cells.
Conserved AREs in the Ifng 3′ UTR determine protein expression
in T cells. We next defined the regulatory region within the Ifng 3′

UTR using deletion mutants. Only reporter constructs containing
the first 241 nucleotides of Ifng 3′UTR reduced GFP MFI similarly
to the GFP-Ifng3′UTR reporter in resting OTI cells and maintained
the induction upon 6 h reactivation with OVA257–264 peptide (Fig. 2a),
indicating that this domain was essential in mediating protein
expression. The mouse Ifng 3′UTR contains six class I AREs, of
which five are located within the first 241 nt (Fig. 2b). Mutating
the ARE located outside of the 241-nt region of the Ifng 3′ UTR
(GFP-IfngMUT6) did not alter the regulatory capacity of the Ifng 3′
UTR (Fig. 2c), while the combined site-directed mutation of all five
AREs located within the proximal 241-nt region (GFP-IfngMUT1–5)
completely abrogated its regulatory activity (Fig. 2c). Resting OTI
cells transfected with GFP-IfngMUT1–5 had a GFP MFI similar to that
of GFPcontrol, which did not increase upon activation with OVA257–264
peptide (Fig. 2c).
Single or double mutants of the five AREs within the proximal
241-nt region only marginally altered the GFP MFI in resting T cells
compared with the GFP-Ifng3′UTR, and activation with OVA257–264
peptide resulted in an incomplete, but significant, increase of GFP
MFI (Supplementary Fig. 2a,b). Mutating the first three AREs
(GFP-IfngMUT1–3), clustered at position 74–98 nt, fully abrogated the
induction of GFP MFI in OVA257–264-activated OTI cells, and this
deletion only partially blocked protein expression in resting T cells
compared to GFPcontrol and GFP-IfngMUT1–5 (Fig. 2d,e). Mutation of
the AREs at position 137–141 nt and 192–196 nt (GFP-IfngMUT4 and
GFP-IfngMUT5, respectively) was required to completely block protein production in resting T cells (Fig. 2d).
The ARE-containing region of the Ifng 3′UTR is highly conserved in human, mouse and many other mammals (Supplementary
Fig. 2c). Human CD4+ and CD8+ T cells transduced with the
human GFP-IFNG3′UTR had lower GFP MFI than T cells transduced with GFPcontrol (Fig. 2f and Supplementary Fig. 2d). As with
mouse IfngMUT1–3, human GFP-IFNGMUT1–3 T cells showed higher
GFP MFI than wild-type GFP-IFNG3′UTR T cells, but 4 h reactivation with PMA plus ionomycin did not increase GFP MFI (Fig. 2f
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Fig. 2 | AU-rich elements within the Ifng 3′ UTR determine protein production in mouse and human T cells. a–e, OTI cells were transduced with
deletion mutants containing the indicated ranges of nucleotides (a) or with ARE mutants of the full-length mouse Ifng 3′UTR (c–e). b, Sequence of
the mouse Ifng 3′UTR. AREs are underlined. a,c, Representative GFP levels of resting OTI cells (gray histograms) and OTI cells after reactivation with
OVA257–264 peptide for 6 h (black lines). d, GFP MFI of resting OTI cells transduced with the indicated ARE mutants. e, Fold increase of GFP MFI upon
activation with OVA257–264 peptide compared to nonactivated GFP-expressing T cells. In d,e, data are presented as mean ±s.d. of at least 3 independently
performed experiments (one-way ANOVA with Dunnett’s multiple comparison to the control vector; n =8 mice per group; *P < 0.005; **P < 0.0005; ns,
not significant). (f) Human T cells were transduced with full-length human GFP-IFNG3′UTR (WT) or with ARE mutants. Dot plots depict GFP MFI levels
from resting T cells (top) or from T cells reactivated with PMA plus ionomycin (iono; bottom), with CD8+ T cells shown in black and CD4+ T cells in gray;
APC, allophycocyanin. Data shown are representative of 4 individuals and of 3 independently performed experiments. Compiled data are depicted in
Supplementary Fig. 2d.

and Supplementary Fig. 2d). In contrast, human GFP-IFNGMUT1–5
T cells expressed GFP MFI comparably to GFPcontrol T cells (Fig. 2f
and Supplementary Fig. 2c). These findings indicate that the highly
conserved proximal region of the IFNG 3′UTR in humans and Ifng
3′UTR in mice blocks protein production in resting T cells through
an ARE-dependent mechanism.
Deletion of Ifng 3′ UTR AREs causes chronic IFN-γ production in TM cells. To investigate the effect of deleting AREs from the
endogenous Ifng mRNA in TM cells, we crossed OTI mice with mice
carrying a germline replacement of the ARE-containing region
with a random sequence (hereafter IFN-γ-ARE-Del OTI mice)16.
To compare the expansion kinetics and cytokine production of
IFN-γ-ARE-Del OTI cells with wild-type OTI cells in response to
830

LM-OVA infection, we transferred equal numbers (500 cells) of
sorted naive CD62LhiCD44loIFN-γ-ARE-Del CD45.2 OTI cells and
wild-type CD45.1 OTI cells into C57BL/6J CD45.1×CD45.2 recipient mice. This ensured an equivalent bacterial load and a similar
cytokine milieu during the course of infection. One day after T cell
transfer, recipient mice were infected with LM-OVA. We followed
the OTI responses to LM-OVA infection by measuring the percentage of IFN-γ-ARE-Del and wild-type OTI cells within the CD8+
T cell population in the blood. At days 6 and 9 postinfection, the
percentage of IFN-γ-ARE-Del and wild-type OTI cells was similar. At day 13, when the infection was cleared, OTI cells contracted
equally (Fig. 3a). At day 35 after LM-OVA infection, similar percentages of OTI cells were found in blood, spleen, liver and bone marrow of C57BL/6J CD45.1×CD45.2 recipient mice (Fig. 3a and data
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Fig. 3 | Deletion of AREs in the Ifng 3′ UTR dysregulates protein production in TM cells. a, Percentage ±s.d. of CD8+ OTI cells in blood drawn from LMOVA-infected mice at the indicated time points (n =8 mice per group). b, Representative dot plots of CD44 versus CD62L expression (left) and of CD127
versus KLRG1 expression (right) of wild-type OTI CD45.1 and IFN-γ-ARE-Del OTI CD45.2 cells 35 d after LM-OVA infection. Numbers in dot plots indicate
percentage of OTI cells in corresponding gates. Compiled data are depicted in Supplementary Fig. 3a. FITC, fluorescein isothiocyanate; BV, brilliant violet;
PerCP, peridinin-chlorophyll proteins; PE, phycoerythrin; Cy, cyanine. c, IFN-γand TNF production measured in blood, spleen, liver and bone marrow (BM)derived TM cells after 3 h incubation with 1 μg /ml BFA. Histograms represent wild-type OTI CD45.1 (gray histograms) and IFN-γ-ARE-Del OTI CD45.2
(black lines) TM cells. Numbers depict percentage of IFN-γ+ and TNF+ T cells. IFN-γand TNF MFI of wild-type and IFN-γ-ARE-Del T cells was compared
using an unpaired Student t-test (n =4 mice per group; *P < 0.05; **P < 0.005; ***P < 0.0005). d, Percentage ±s.d. of IFN-γ-producing T cells from spleenresiding wild-type (gray square) and IFN-γ-ARE-Del (white square) CD44hiCD62LloCD127lo TEFF, CD44hiCD62LloCD127hi TEM, CD44hiCD62LhiCD127hi
TCM, KLRG1hiCD127lo SLEC and KLRG1loCD127hi MPEC cells 35 d after LM-OVA infection (unpaired Student t-test; n =4 mice per group; **P < 0.005;
***P < 0.0005). e, Ifng mRNA expression, normalized to Rpl32 (L32), in sorted splenic wild-type or IFN-γ-ARE-Del OTI TM cells 35 d after LM-OVA
infection (pooled from 4 mice). In a–e, data shown are representative of 2 independently performed experiments. f,g, IFN-γprotein (left) and mRNA levels
(right) of sorted spleen-derived (f) and liver-derived (g) CD44hiCD8+ wild-type and IFN-γ-ARE-Del OTI cells. Representative dot plots of 4 mice. mRNA
data ±s.d. are pooled from 4 independently performed experiments. In e–g, unpaired Student t-test; ns, not significant.

not shown). In addition, the percentage of CD44hiCD62LloCD127lo
effector T (TEFF) cells, CD44hiCD62LloCD127hi effector memory T
(TEM) cells and CD44hiCD62LhiCD127hi central memory T (TCM)
cells, as well as the percentage of KLRG1hiCD127lo short-lived
effector cells (SLEC) and KLRG1loCD127hi memory precursor cells
(MPEC), was indistinguishable between IFN-γ-ARE-Del and wildtype OTI cells (Fig. 3b and Supplementary Fig. 3a).
Despite the normal differentiation into TEFF and TM cells, bloodderived IFN-γ-ARE-Del OTI cells isolated from CD45.1×CD45.2
recipient mice on day 35 postinfection produced IFN-γeven in the
absence of peptide restimulation, as defined by intracellular cytokine staining after 3 h of incubation with brefeldin A (BFA) (Fig.
3c). The IFN-γproduction was also detected in spleen-, liver- and
bone marrow–derived IFN-γ-ARE-Del OTI cells 35 d postinfection

(Fig. 3c), as well as in spleen- and liver-derived IFN-γ-ARE-Del OTI
cells 48 d postinfection (Supplementary Fig. 3b). In contrast, wildtype OTI cells that were transferred into the same CD45.1×CD45.2
recipient mice did not produce IFN-γ (Fig. 3c and Supplementary
Fig. 3b). Wild-type and IFN-γ-ARE-Del T cells also did not produce
TNF (Fig. 3c). At day 35 postinfection all liver and spleen-derived
IFN-γ-ARE-Del T cells—TEFF cells, TEM cells, TCM cells, SLECs and
MPECs—produced IFN-γ, as determined by the percentage and
MFI of IFN-γprotein (Fig. 3d and Supplementary Fig. 3c,d).
The expression of Ifng mRNA was similar in sorted IFN-γ-AREDel and wild-type OTI cells at day 35 postinfection (Fig. 3e), indicating that IFN-γproduction of IFN-γ-ARE-Del OTI cells did not
correlate with increased mRNA expression. To determine whether
this leaky IFN-γproduction also occurs in other settings, we studied
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naturally occurring CD44hi memory-like T cells. Like infectioninduced TM cells, spleen-derived CD44hi sorted OTI cells mediate
protection to LM-OVA infection by rapidly producing IFN-γ upon
832

antigen exposure31. CD44hi OTI cells expressed more Ifng mRNA
than naive CD44lo OTI cells (Supplementary Fig. 3e). Only CD44hi
IFN-γ-ARE-Del cells produced IFN-γex vivo when cultured for 4 h
in the absence of stimulation (Fig. 3f,g and Supplementary Fig. 3f,g).
Yet the Ifng mRNA levels of IFN-γ-ARE-Del OTI cells were comparable to those of wild-type CD44hi OTI cells (Fig. 3f,g). Again, the
IFN-γproduction was observed in spleen-derived CD44hiCD62Llo
TEFF and TEM cells and in CD44hiCD62Lhi TCM cells from
IFN-γ-ARE-Del mice (Supplementary Fig. 3f,g), but not from wildtype mice, whereas T cells from both genetic backgrounds expressed
identical Ifng mRNA levels (Supplementary Fig. 3h). Thus, the ARE
region within the Ifng mRNA controls the production of IFN-γ in
TM cells by post-transcriptional mechanisms.
The ARE-binding protein ZFP36L2 interacts with Ifng mRNA. To
investigate how AREs prevent the production of IFN-γin TM cells,
we pulled down the ARE-binding proteins from cytoplasmic cell
lysates of in vitro expanded, resting primary human T cells using
the streptavidin-binding RNA aptamer 4xS1m32, which expresses
the 189-nt ARE region of the human IFNG 3′UTR, and analyzed
them by mass spectrometry. To reduce false positive results, we
included the empty 4xS1m RNA aptamer lacking the ARE region as
a control (4xS1m-empty) and performed the purifications in triplicate. ARE binding was scored positive when a protein was identified
in all three samples. This analysis identified 83 proteins that bound
IFNG-4xS1m but not 4xS1m-empty. Fifty-seven proteins were significantly enriched (Student t-test, false discovery rate (FDR) =  0.05,
scatter S0 = 0.4) upon purification with the IFNG-4xS1m construct
(Fig. 4a). To validate ARE-specific binding, we performed a second
purification that included the human IFNGMUT1–5 variant, IFNGMUT1–
5-4xS1m. Eighty out of the 83 proteins found in the first purification
were also detected in the second purification. Of these, we identified
two proteins, ZFP36L1 and ZFP36L2, that interacted with IFNG4xS1m but not with IFNGMUT1–5-4xS1m or with 4xS1m-empty
(Fig. 4a and Supplementary Fig. 4a–d).
ZFP36L1 (TIS11B) and ZFP36L2 (TIS11D) are ZFP36 (tristetraprolin or TTP)-family proteins, which bind AREs33,34. ZFP36
induces cytokine-encoding mRNA degradation in T cells, and
ZFP36-deficient mice develop severe autoimmunity due to excessive
cytokine production35,36. We detected more Zfp36l2 than Zfp36l1
mRNA in spleen-derived CD44hiCD8+ T cells, along with more
ZFP36L2 than ZFP36L1 protein (Fig. 4b,c). Furthermore, ZFP36L2
protein expression was comparable in naive T cells, in CD44hi TM
cells and in TM cells reactivated with PMA plus ionomycin, while
ZFP36L1 was only detectable upon T cell activation (Supplementary
Fig. 4e). Native RNA immunoprecipitation (i.e., immunoprecipitation without cross-linking) showed that Ifng mRNA was enriched
in ZFP36L2 pulldowns from resting T cells, but not from resting
IFN-γ-ARE-Del T cells (Fig. 4d). Thus, ZFP36L2 interacts specifically with the ARE region of the Ifng 3′ UTR.
ZFP36L2 represses IFN-γ production independently of mRNA
stability. Next we used mice with a conditional deletion of ZFP36L2
in the T cell lineage37 to assess the role of ZFP36L2 deficiency in
CD44hi memory-like T cells. CD4-Cre Zfp36l2flox/flox mice (hereafter Zfp36l2cKO) had a similar percentage of CD8+ and CD4+ TEFF,
TEM and TCM cell subsets in the spleen to their wild-type littermates
(Supplementary Fig. 5a). However, spleen-derived CD44hi CD8+
and CD4+ T cells from Zfp36l2cKO mice, but not from wild-type littermates, produced IFN-γin the absence of stimulation (Fig. 5a,b),
whereas Ifng mRNA amounts were comparable to those in wildtype CD44hi T cells (Fig. 5a,b).
We next tested whether loss of ZFP36L2 also affected the GFP
reporter constructs. We transduced wild-type and Zfp36l2cKO T cells
with GFPcontrol, GFP-Ifng3′UTR or GFP-IfngMUT1–5. The GFP MFI of
GFP-IfngMUT1–5 T cells and GFPcontrol T cells was comparable in resting
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Fig. 5 | The ARE-binding protein ZFP36L2 represses IFN-γ production in TM cells. a,b, IFN-γproduction of sorted splenic CD44hiCD8+ (a) and
CD44hiCD4+ (b) T cells from Zfp36l2cKO mice compared to wild-type littermates after 3 h incubation with BFA (top; n =6 mice per group) and
IFN-γ-ARE-Del mice compared to C57BL/6 J wild-type mice (bottom; n =5 mice per group). Left: representative dot plot. Middle: compiled data
(mean ±s.d.) depicting the fold increase of IFN-γproduction compared to wild-type mice. Right: Ifng mRNA expression levels ± s.d. c, T cells from
Zfp36l2cKO mice and wild-type littermates were retrovirally transduced with GFP-Ifng3′UTR, GFPMUT1–5 or GFPcontrol. Left: dot plots represent GFP expression
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wild-type and Zfp36l2cKO T cells (Fig. 5c,d). In contrast, GFP MFI
was substantially increased in GFP-Ifng3′UTR CD8+ T cells and in
CD4+ Zfp36l2cKO T cells compared to wild-type T cells (Fig. 5c,d),
indicating that ZFP36L2 represses IFN-γproduction in T cells.
AREs are primarily associated with the regulation of mRNA stability16,17,35,38. The overall amount of mRNA depends on the transcription rate and the rate of mRNA decay. We measured the rate
of mRNA decay by treating resting OTI cells with the polymerase
II transcription inhibitor actinomycin D (ActD). Ifng mRNA had
a longer half-life in IFN-γ-ARE-Del OTI cells (t1/2 > 120 min) than
in wild-type OTI cells (t1/2 ~30 min; Fig. 5e). The half-life of Ifng
dropped to t1/2 ~60 min in sorted CD44hi IFN-γ-ARE-Del OTI
cells, compared to t1/2 ~30 min in wild-type OTI cells (Fig. 5f).
Following 120 min of ActD treatment, the decay of Ifng mRNA
in IFN-γ-ARE-Del OTI cells was similar to that in wild-type OTI
cells (Fig. 5f), indicating that the Ifng mRNA stability ex vivo is
substantially lower than in vitro. This was not the case for other
transcripts, as Tnf remained unstable and 18S remained stable

(Supplementary Fig. 5b–e). Similar data were obtained using
polyclonal CD4+ and CD8+CD44hi T cells from IFN-γ-ARE-DEL mice
(Fig. 5g and Supplementary Fig. 5f). The rate of Ifng mRNA decay in
Zfp36l2cKO CD4+ and CD8+ CD44hi T cells was comparable to that in
IFN-γ-ARE-DEL T cells (Fig. 5h and Supplementary Fig. 5g), indicating the ARE-independent degradation of Ifng mRNA did not
require ZFP36L2. In addition, the amount of miR-29a and miR-29b,
which can affect Ifng mRNA expression39,40, and the expression of
Tbx21 and Eomes mRNA, which encode the transcription factors
T-bet and eomesodermin, were similar in IFN-γ-ARE-Del and
wild-type CD44hi TM cells (Supplementary Fig. 5h), suggesting that
the expression of these factors was not influenced by IFN-γ-AREDel-mediated alterations in TM cells. As such, Ifng AREs determine
Ifng mRNA stability depending on the activation status of T cells,
and they do so in a ZFP36L2-independent manner.
ZFP36L2 blocks the association of Ifng mRNA to ribosomes in
TM cells. We next examined whether AREs modulate transcription
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and translation of Ifng mRNA in TM cells. We treated spleen-derived
IFN-γ-ARE-Del CD44hi memory-like T cells with ActD or the
translation inhibitor cycloheximide (CHX) and measured IFN-γ
production in the absence of stimulation. Blocking transcription
with ActD did not interfere with IFN-γproduction in IFN-γ-AREDel CD44hi T cells (Fig. 6a,b). We did not detect TNF production in
these cells, and cell viability and the surface markers CD8 and CD44
were unaltered (Supplementary Fig. 6a). In contrast, treatment with
CHX, which inhibits protein translation, blocked the production of
IFN-γin IFN-γ-ARE-Del CD44hi T cells compared to ActD-treated
cells (Fig. 6a,b), indicating that the IFN-γproduction depends on
translation and that the pre-formed Ifng mRNA serves as template
for protein production in IFN-γ-ARE-Del CD44hi TM cells.
To test whether AREs impair the translation of pre-formed Ifng
mRNA, we measured the association of Ifng mRNA with ribosomes
in spleen-derived IFN-γ-ARE-Del or wild-type CD44hi T cells. The
heavy fraction of cytosolic extracts was pelleted by sucrose cushion
centrifugation to enrich for ribosomes41. As a control, half of the
each cytosolic extract was treated with 20 mM EDTA, which dissociates ribosomal and ribosome-associated proteins from mRNA41
(Supplementary Fig. 6b). mRNA levels measured from this control
sample included residual binding of Ifng mRNA to ribosomes and
unbound Ifng mRNA, and were subtracted from those of the pellets
of EDTA-untreated sucrose cushions. Only the Ifng mRNA from
IFN-γ-ARE-Del CD44hi T cells, but not from wild-type CD44hi
T cells, associated with ribosomes (Fig. 6c). The association of control mRNAs Tnf and 18S was comparable between wild-type and
IFN-γ-ARE-Del CD44hi T cells (Supplementary Fig. 6c,d). Notably,
the Ifng mRNA from CD44hiCD4+ and CD44hiCD8+ Zfp36l2cKO
T cells also associated with ribosomes (Fig. 6d,e), indicating that
834

the recruitment of Ifng mRNA to the ribosome depended at least in
part on ZFP36L2. Thus, AREs within the Ifng mRNA and ZFP36L2
suppress the translation of IFN-γprotein from pre-existing mRNA
in TM cells.
ZFP36L2 binds to pre-formed mRNA in memory T cells. To
determine whether ZFP36L2 blocks the translation of other AREcontaining mRNAs that are rapidly translated in TM cells upon
activation, we sorted spleen-derived CD44hi memory-like OTI
cells and performed mass spectrometry on untreated cells and on
T cells activated for 2 h with OVA257–264 peptide. Of the 5,490 identified proteins, 54 significantly altered their expression profile upon
T cell activation (Student t-test, FDR =  0.05, S0 =  0.4; Fig. 7a and
Supplementary Fig. 7a). Seventeen proteins were significantly less
abundant in stimulated T cells, including CD62L (Sell; Fig. 7a),
which is rapidly downregulated upon T cell activation. Conversely,
37 proteins were significantly induced in stimulated CD44hi OTI
cells, including the early activation marker CD69 and the proinflammatory cytokines IFN-γ, TNF and interleukin-2 (Fig. 7a). Of
note, 32 of these 37 proteins were generated from ARE-containing
mRNAs (Fig. 7a and Supplementary Fig. 7a).
We next determined the mRNA levels of these rapidly induced
proteins in TM cells. Fifty-two out of the 54 proteins that altered their
expression profile upon activation of CD44hi OTI cells were annotated in TEM and TCM cells specific for the lymphochoriomeningitis
virus (LCMV)42. The mRNAs for the 17 proteins that were enriched
in the CD44hi OTI cells were also expressed in LCMV-specific TEM
and TCM cells (Fig. 7b and Supplementary Fig. 7b). The mRNAs of
the 35 proteins that were rapidly induced in CD44hi OTI cells greatly
varied in expression in TEM and TCM cells (Fig. 7b and Supplementary
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Fig. 7b). LCMV-specific TEM and TCM cells expressed the mRNAs
for 29 of the 35 (82.9%) rapidly generated proteins (Fig. 7b
and Supplementary Fig. 7b). For 22 of these 35 proteins (62.9%),
the peptide abundance was below detection limit in nonactivated
CD44hi T cells (Supplementary Fig. 7a), indicating that these 22
mRNAs are putatively blocked from translation in TM cells.
ZFP36L2 binds to ARE-containing mRNA with a tandem zinc
finger43 that requires two AREs for interaction. Of the 35 rapidly
induced proteins, 26 ARE-containing transcripts included at least
2 AREs (defined as AUUUA) within the 3′UTR (Supplementary
Table 1). We focused on 11 putative target genes that fulfilled the following criteria: they contained two AREs in most of their transcript
variants (Supplementary Table 1) and they expressed pre-formed
mRNA in TM cells (Supplementary Fig. 7b). We measured ZFP36L2
binding to these endogenously expressed mRNAs using native RNAimmunoprecipitation in resting OTI cells. Of the 11 tested mRNAs,
6 mRNAs were significantly enriched in resting T cells compared to
the immunoglobulin G (IgG) control pulldown: Ifng, Tnf, Irf4, Junb,
Zfp36l1 and Pim1 (Fig. 7c). This indicates that ZFP36L2 targets several ARE-containing pre-formed mRNAs TM cells.
ZFP36L2 rapidly releases pre-formed mRNA upon activation.
Because pre-formed mRNA drives rapid cytokine production upon
T cell activation15, we tested whether T cell activation supports the

release of pre-formed mRNA from ZFP36L2. As determined by
RNA-immunoprecipitation, ZFP36L2 binding to Ifng mRNA was
significantly reduced in OTI cells reactivated with OVA257–264 for 2 h
compared to nonactivated, resting OTI cells (Fig. 7d). Of note, loss of
mRNA binding upon reactivation coincided with rapid downregulation of Zfp36l2 mRNA, but ZFP36L2 protein remained unaltered
(Supplementary Fig. 7d). ZFP36L2 also rapidly dissociated from
Tnf and Pim1 mRNA upon T cell activation, while its binding to
Irf4, Junb and Zfp36l1 mRNA did not change compared to that in
nonactivated T cells (Fig. 7d). Peptides for IFN-γ, TNF and Pim1
were below detection limit in nonactivated CD44hi T cells in the proteomics analysis (Supplementary Fig. 7a), further pointing to a block
of mRNA translation. Tnf mRNA was significantly enriched in the
ribosome-enriched fraction of Zfp36l2cKO CD8+ and CD4+CD44hi
T cells compared to wild-type T cells (Fig. 7e), and TNF production
was found in CD8+ and CD4+CD44hi T cells in the absence of stimulation (Fig. 7f). These observations thus show that ZFP36L2 suppresses the translation of several target mRNAs in memory T cells.

Discussion

Here we found that the translation of pre-formed Ifng mRNA was
actively repressed in TM cells. All five highly conserved AREs of
the Ifng 3′UTR contributed to the translational block, which may
render this regulatory mechanism refractory to single nucleotide
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polymorphisms. The ARE-binding protein ZFP36L2 mediated the
translational silencing of pre-formed mRNA in TM cells. Germline
deletion of the entire ARE-containing region and ZFP36L2 deficiency in TM cells caused aberrant recruitment of pre-formed Ifng
mRNA to ribosomes and led to IFN-γprotein production in the
absence of activation. ZFP36L2 not only controlled the translation
of Ifng, but also of Tnf and Pim1 mRNAs, encoding other rapidly
induced proteins. Thus, the ARE-dependent inhibition of translation keeps TM cells silent in the absence of infection.
TM cells continuously receive tonic signals through cytokines
and/or through their TCR that support their maintenance44–46.
Tonic signaling drives the constitutive expression of unstable cytokine mRNA47. We postulate that the active suppression of cytokine
production is required to maintain TM cells silent in the absence of
the infection. Whether tonic signaling also controls the function
of ZFP36L2 is yet to be determined. Once TM cells become reactivated, pre-formed mRNA is rapidly disengaged by ZFP36L2, allowing the immediate production of protein. Because the expression of
ZFP36L2 protein was not altered, ZFP36L2 could remain ready for
rapid re-engagement, target other mRNAs, or exert different functions in stimulated T cells.
ZFP36L1 mRNA and protein expression was lower in
TM cells than that of ZFP36L2, and the contribution of ZFP36L1
to the blockade of translation in TM cells may therefore be limited.
However, because the binding of ZFP36L2 to mRNA is rapidly lost
upon activation, ARE-mediated regulation may be highly versatile
and dependent on the context. It is therefore conceivable that ZFP36
and ZFP36L1 drive post-transcriptional events at other stages of
T cell differentiation or activation. This also may hold true for other
RBPs, such as TIA, which limits excessive TNF production through
a translational block in lipopolysaccharide-stimulated macrophages48. Similar regulatory mechanisms may also occur in T cells,
depending on the activation status.
The biological relevance of ARE-mediated cytokine production
was highlighted by the germline deletion of AREs in the Ifng 3′ UTR
or the Tnf 3′UTR, which lead to chronic cytokine production and
consequentially to autoimmune disease in mice16,17. Sixteen percent of human protein-coding genes are thought to contain AREs49.
Cytokine and chemokine mRNA transcripts are highly enriched
for these sequences20,26, pointing to a specific role of AREs in the
effector function of T cells. Also, the rapidly responding NK cells,
NKT cells and myeloid cells constitutively express mRNAs encoding effector molecules50,51. Conversely, self-reactive CD4+ T cells
maintain their anergic phenotype by blocking the translation of
cytokine mRNAs52. It is therefore tempting to speculate that the
ARE-dependent translational repression described here is more
broadly employed to regulate immune responses.
In conclusion, we identified a conserved mechanism that tightly
regulates the translation of pre-formed cytokine mRNAs in CD8+
and CD4+ TM cells. Considering that tissue-resident CD8+ TM cells
express even higher levels of mRNA encoding effector molecules than
circulating TM cells53, our findings suggest that manipulation of AREmediated post-transcriptional control may be exploited to rectify
impaired T cell responses in tissues, as, for example, against tumors.

Methods

Methods, including statements of data availability and any associated accession codes and references, are available at https://doi.
org/10.1038/s41590-018-0155-6.
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Methods

Mice and cell culture. Mice were obtained from Charles River or housed and
bred in-house at the Netherlands Cancer Institute (NCI). IFN-γ-ARE-Del mice
were generated as previously described16 and crossed to C57BL/6J.OTI T cell
receptor (TCR) transgenic mice (OTI). Mice carrying a conditional allele of
Zfp36l2 have been previously described37 and were crossed to mice in which the
Cre recombinase is expressed under the control of mouse CD4 regulatory elements
(Tg(CD4-cre)1Cwi) to obtain deletion specifically in T cells55. Experiments were
performed in accordance with institutional and national guidelines and approved
by the Experimental Animal Committee at the NCI.
Cells were cultured at 37 °C and 5% CO2 in IMDM (Gibco-BRL) containing
8% FCS, 2 mM l-glutamine, penicillin and streptomycin, supplemented for mouse
cells with 15 μM 2-mercaptoethanol.
Cloning. Gene-specific 3′UTRs were amplified from genomic DNA of a C57BL/6J
mouse or from human genomic DNA (sequences upon request). The 3′ UTR
variants were cloned into the ClaI site of pRETRO-SUPER GFP56 downstream of
GFP. 189 nt of the human IFNG 3′UTR were cloned into the pSP73-4xS1m32. The
region containing the streptavidin binding sites was reversed using the two BglII
sites, and the IFNG 3′UTR was inserted into the 5′end of the S1m motifs. Prior
to in vitro transcription, the pSP73-4xS1m construct was linearized with NdeI.
ARE mutants with a substitution of AUUUA sequence by AAAAA were obtained
from GeneScript and subcloned into pRS-GFP or pSP73-4xS1m. Sequences were
confirmed by sequence analysis.
T cell activation and retroviral transduction. 1.5 ×  106 human PBMCs were
activated in a 24-well plate for 40 h with plate-bound anti-CD3 and anti-CD28
(1 μg/ml each, eBioscience). Retroviral transduction was performed with
Retronectin (Takara) as described57, and cells were maintained in culture in the
presence of 20 ng/ml recombinant human interleukin-7 (PeproTech).
1 ×  106 CD8-purified OTI T cells (Miltenyi CD8 isolation kit; 90–99%
purity) were cultured for 20 h with 0.1 ×  106 preseeded MEC.B7.SigOVA cells as
described58. 3 ×  106 C57BL/6 J splenocytes were activated for 48 h with concanavalin
A (2 μg/ml, Sigma) and recombinant mouse interleukin-7 (rmIL-7, 1 ng/ml,
PeproTech), or with plate-bound anti-CD3 (2 μg/ml, eBioscience) and soluble
anti-CD28 (1 μg/ml, Bioceros). Cells were harvested and retrovirally transduced
as described59. T cells were maintained with 10 ng/ml rmIL-7 and reactivated with
100 nM or 1 μM OVA257–264, or with 10 ng/ml PMA and 1 μM ionomycin (Sigma).
FACS-sorted CD8+ and CD4+CD44hi T cells were isolated from spleen or liver
of 6- to 9-week-old mice. T cells were incubated for 4 h with brefeldin A (BFA),
with or without 1 μg/ml actinomycin D (ActD) or 10 μg/ml cycloheximide
(CHX) (Sigma).
Adoptive T cell transfer and L. monocytogenes–OVA infection. GFP-expressing
OTI T cells were purified with Lympholyte M (Cedarlane) and FACS-sorted for
GFP expression. Naive CD8+CD44loCD62Lhi WT and IFN-γ-ARE-Del OTI T cells
were FACS-sorted from splenocytes. One thousand GFP+ OTI T cells, or 500 naive
WT OTI CD45.1+ together with 500 naive IFN-γ-ARE-Del OTI CD45.2+ T cells,
were adoptively transferred into recipient mice. The next day, mice were infected
i.v. with 2.5 ×  103 or 2.5 ×  104 colony-forming units (CFU) of a L. monocytogenes
strain expressing ovalbumin (LM-OVA). Peripheral blood was drawn to monitor
T cell responses. 35–48 d after infection, spleen, liver and bone marrow cells were
incubated with brefeldin A alone or reactivated for 6 h with 1 μg/ml OVA257–264, and
intracellular staining for IFN-γwas performed.
Flow cytometry. Mouse T cells were labeled for 20 min at 4 °C with anti-CD3
(17A2), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD45.1 (A20), anti-CD45.2
(104), anti-Vβ5.1–5.2 (MR9-4), anti-CD44 (IM7), anti-CD62L (MEL-14), antiCD127 (A7R34), anti-KLRG1 (MAFA), anti-IFN-γ(XMG1.2) and anti-TNF-α
(MP6-XT22) (all eBioscience). Human T cells were labeled with anti-CD3
(UCHT1, Beckman Coulter), anti-CD4 (SK3, BD Biosciences), anti-CD8 (SK1,
BD Biosciences). Dead cells were excluded with 1 ng/ml TO-PRO-3 iodide
(Sigma-Aldrich) or Near-IR (L10119, Life Technology). Intracellular cytokine
staining was performed with the Cytofix/Cytoperm kit (BD Biosciences). Flow
cytometry analysis was performed on LSR-II and LSR Fortessa (BD Biosciences).
Data were analyzed with FlowJo software (Tree Star, version 7.6.5 and version 10).
Representative flow cytometry gating strategies are found in Supplementary Fig. 8.
Quantitative PCR analysis. Total RNA was extracted using Trizol (Invitrogen)
and cDNA was synthesized with SuperScript III (Invitrogen), unless otherwise
specified. miRNAs were extracted from FACS-sorted CD8+CD44hi WT and
IFN-γ-ARE-Del OTI T cells using the Total RNA Purification Plus Kit (Norgen
Biotek), and cDNA was synthesized with the miScript II RT kit (Qiagen). RT-PCR
was performed with triplicate reactions using SYBR Green on a StepOne Plus (both
Applied Biosystems; for primer sequences, see ref. 58). Ct values were normalized to
L32 levels and confirmed with 18S.
RNA immunoprecipitation and immunoblot. Cytoplasmic lysates of resting
WT or IFN-γ-ARE-Del OTI T cells (250 ×  106 cells per condition) were prepared
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using lysis buffer (10 mM HEPES, pH 7.0, 100 mM KCl, 5 mM MgCl2, 0.5% NP40)
freshly supplemented with 1 mM DTT, 40 U/ml RNase OUT (both Invitrogen),
0.4 mM vanadylribonucleoside complex RNase inhibitor (NEB) and 1% EDTA-free
protease/phosphatase inhibitor cocktail (Thermo Scientific). Protein G Dynabeads
(Thermo Scientific) were prepared as previously described60. The lysate was
immunoprecipitated for 2 h at 4 °C with polyclonal rabbit anti-ZFP36L2 (ab70775)
or a polyclonal rabbit IgG isotype control (ab27478, both Abcam). RNA was
extracted directly from beads by using Trizol, and mRNA expression was measured
by RT-PCR as described above. Specificity of the RNA-IP assay was tested by
immunoblotting using a rat pan-ZFP36 antibody generated in the laboratory of
M. Turner (unpublished data). This antibody is directed against the C terminus of
ZFP36L1 and recognizes all three ZFP36 family members.
1 ×  106 FACS-sorted CD8+CD44lo and CD8+CD44hi T cells were lysed according
to standard procedures. Proteins were separated on a 10% SDS–PAGE gel and
transferred onto a nitrocellulose membrane by iBlot (Thermo). Rabbit polyclonal
anti-ZFP36L1 (ab42473), rabbit polyclonal anti-ZFP36L2 (ab70775, both Abcam),
mouse monoclonal anti-RhoGDI (MAB9959, Abnova), mouse monoclonal
anti-GAPDH (MAB374, Millipore), and a rat pan-ZFP36 antibody were used as
primary antibodies, followed by goat anti-rabbit-HRP (4050-05), goat anti-mouseHRP (1031-05, both Southern Biotech) or goat anti-rat-HRP (31470, Invitrogen)
secondary antibodies.
Sucrose cushion. 1 ×  106 FACS-sorted CD8+ CD44hi WT or IFN-γ-ARE-Del
OTI T cells were lysed in modified polysome buffer (20 mM Tris-HCl, pH 7.5,
300 mM KCl, 5 mM MgCl2, 0.50% NP40) freshly supplemented with 2 mM DTT,
40 U/ml RNase OUT and 10 μg/ml CHX. Total cell lysate was treated or not
with 20 mM EDTA, pH 8.0 (Invitrogen), layered over a 20% sucrose cushion
and then centrifuged at 37,500 r.p.m. at 4 °C for 2 h in a SW60Ti swing-out rotor
ultracentrifuge (Beckman Coulter). RNA was isolated from the pellet using a Total
RNA Purification Plus Kit (Norgen Biotek), and mRNA expression levels were
analyzed by RT-PCR. The distribution of transcripts within the ribosome-enriched
fraction was calculated as fold increase relative to the amount of transcript
precipitated in the corresponding EDTA-treated sample.
4xS1m RNA aptamer-protein pulldown. Human resting T cells were washed
with PBS and the cell pellet was snap frozen in liquid nitrogen. The cell pellet was
homogenized using 5-mm steel beads and a tissue lyser (Qiagen TissueLyser II)
at 25 Hz for 15 s six times. The homogenate was then solubilized and precleared
as previously described32. The 4xS1m RNA aptamers containing or not the 189
nt of the human IFNG 3′UTR were in vitro transcribed using the Ampliscribe
T7-flash transcription kit (Epicentre) and coupled to Streptavidin Sepharose High
Performance beads (GE Healthcare) as described32. RNA-coupled beads and cell
lysate were incubated for 3.5 h at 4 °C under rotation in the presence of
60 U RNasin (Ambion). For each pulldown, about 30 μg in vitro transcribed
RNA and 10 mg protein were used. RNA-bound proteins were eluted by adding
1 μg RNaseA (Thermo Scientific) and 100 μl 100 mM Tris-HCl, pH 7.5 (GibcoInvitrogen). Proteins were reduced, alkylated and digested into peptides using
trypsin. Peptides were desalted and concentrated using Empore-C18 StageTips61
and eluted with 0.5% (v/v) acetic acid, 80% (v/v) acetonitrile. Sample volume was
reduced by SpeedVac and supplemented with 2% acetonitrile, 0.1% TFA.
Proteomic analysis of OTI memory T cells. Triplicates of 2 ×  106 FACS-sorted
CD8+ CD44hi OTI T cells were incubated for 2 h in IMDM containing 5% FCS and
1 μg/ml BrfA with or without the presence of 100 nM OVA257–264 peptide. Cells were
washed twice with ice-cold PBS and cell pellets were snap frozen in liquid nitrogen.
Cells were lysed in 40 μl 1% sodium deoxycholate, 40 mM chloroacetamide (both
Sigma Aldrich), 10 mM TCEP (Thermo Scientific) and 100 mM Tris-HCl, pH 8
(Life Technologies), boiled at 95° for 5 min and sonicated for 10 min in a Sonifier
bath (Branson). An equal volume of 50 mM ammonium bicarbonate (Sigma
Aldrich) was added, containing 600 ng Trypsin Gold (Promega). Samples were
digested overnight at room temperature, acidified by addition of 1 μl trifluoroacetic
acid (Thermo Scientific) and loaded on in-house-prepared SDB-RPS StageTips
(Empore). Peptides were desalted and eluted in three fractions by increasing
concentrations of ammonium formate (100 mM and 150 mM) or 5% (v/v)
ammonium hydroxide and acetonitrile (40%, 60% and 80% v/v)62. Sample volume
was reduced by SpeedVac and supplemented with 2% acetonitrile, 0.1% TFA.
Mass spectrometry data acquisition. Tryptic peptides were separated by nanoscale
C18 reverse chromatography coupled online to an Orbitrap Fusion Tribrid mass
spectrometer via a NanoElectroSpray Ion Source (both Thermo Scientific). Peptides
were loaded on a 20-cm 75–360 µm inner-outer diameter fused silica emitter (New
Objective) packed in-house with ReproSil-Pur C18-AQ 1.9-μm
resin (Dr Maisch GmbH). The column was installed on a Dionex Ultimate3000 RSLC
NanoSystem (Thermo Scientific) using a MicroTee union formatted for 360 μm
outer diameter columns (IDEX) and a liquid junction. The spray voltage was set
to 2.15 kV. Buffer A was composed of 0.5% acetic acid and buffer B of 0.5% acetic
acid, 80% acetonitrile. Peptides were loaded for 17 min at 300 nl/min at 5% buffer
B, equilibrated for 5 min at 5% buffer B (17–22 min) and eluted by increasing
buffer B from 5 to 15% (22–87 min) and 15 to 38% (87–147 min), followed by a
Nature Immunology | www.nature.com/natureimmunology
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10-min wash to 90% and a 5-min regeneration to 5%. Survey scans of peptide
precursors from 400 to 1,500 m/z were performed at 120 K resolution (at 200 m/z)
with a 1.5 ×  105 ion count target. Tandem mass spectrometry was performed by
isolation with the quadrupole with isolation window 1.6, HCD fragmentation with
normalized collision energy of 30 and rapid scan mass spectrometry analysis in
the ion trap. The MS2 ion count target was set to 104 and the maximum injection
time was 35 ms. Only those precursors with charge states 2–7 were sampled for
MS2. The dynamic exclusion duration was set to 60 s with a 10-p.p.m. tolerance
around the selected precursor and its isotopes. Monoisotopic precursor selection
was turned on. The instrument was run in top speed mode with 3-s cycles. All data
were acquired with Xcalibur software.
Mass spectrometry data analysis. The RAW mass spectrometry files were
processed with the MaxQuant computational platform, 1.5.0.25 (RNA pulldown)
or 1.6.0.13 (memory OTI T cells)63. Proteins and peptides were identified using the
Andromeda search engine by querying the human Uniprot database (downloaded
February 2015, 89,796 entries) for the RNA pulldown, or the mouse Uniprot
database (downloaded 18 August 2017, 51,434 entries) for analysis of memory OTI
T cells. Standard settings with the additional options match between runs, labelfree quantification (LFQ), and unique peptides for quantification were selected.
The generated ‘proteingroups.txt’ table was filtered for potential contaminants
and reverse hits using Perseus 1.5.0.31 (RNA pulldown) or 1.5.1.6 (memory
OTI T cells). The LFQ values were transformed in log2 scale, the triplicates per
experimental condition grouped, and proteins filtered for at least three valid
values in one of the experimental groups. Missing values were imputed by normal
distribution (width =  0.3, shift = 1.8), assuming these proteins were close to the
detection limit. To identify the proteins with the most prominent differences, we
performed a two-sided t-test using an FDR of 5% and S0 of 0.4 (volcano plot).
Mass spectrometry data of resting and activated memory T cells (Fig. 7 and
Supplementary Fig. 7) are deposited at PRIDE: PXD008051.
mRNA expression analysis and ARE determination. mRNA expression of
LCMV-specific spleen-derived central memory (CM) and effector memory (EM)
T cells was extracted from Mackay et al.42 (GEO accession code GSE70813). Reads
per million mapped reads (RPM) were transformed as log2-normalized counts
using DESeq264.
To determine the presence of ARE sequences in mRNAs, the 3′UTR sequences
of all mouse transcripts were downloaded from Ensembl BioMart (release May
2015) and compared to transcripts present in an RNA-seq dataset of memory
T cells42. AREs (sequence motif ATTTA) were counted in all 3′UTR variants.
When multiple transcripts were present for a gene, we used the minimum,
maximum and average count of AREs. Resulting data were combined with gene
expression data by gene symbols.
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Statistical analysis. Statistical analysis between groups was performed with
GraphPad Prism 6, using the two-tailed Student t test when comparing two groups
or one-way ANOVA test with Dunnett correction when comparing more than two
groups. P values < 0.05 were considered statistically significant.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data and code availability. The materials, data, code and any associated protocols
that support the findings of this study are available from the corresponding
author upon reasonable request. The MS datasets have been deposited in the
ProteomeXchange database under accession code PXD008051.
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Experimental design

1. Sample size
Describe how sample size was determined.

For in vivo mouse experiments, sample size was determined for each experiment with the
use of the guideline book of van Zutphen et al.: Proefdieren en dierproeven (translated:
'experimental animals and animal experiments'), as required and approved by the
Experimental Animal Committee.
For in vitro experiments, the sample size was determined based on pilot experiments or
previous studies. All experiments included at least 3 biological replicates and all
experiments were performed at least twice. Data are compiled from independent
experiments.
Western blots are representative of three independently performed experiments.
Each mass spectrometry experiment includes 3 biological replicates per group.
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2. Data exclusions
Describe any data exclusions.

For the in vivo experiments all analyzed mice are included for analysis.
For in vitro data, data exclusion was only applied when positive and/or negative controls of
an experimental repeat demonstrated a failure of the experimental procedure.

3. Replication
Describe the measures taken to verify the reproducibility
of the experimental findings.

All data are reliably reproduced, and compiled from independent experiments in figures and
statistical analysis as indicated in the figure legends.

4. Randomization
Describe how samples/organisms/participants were
allocated into experimental groups.

Randomization was not applicable in this study.
In vivo studies required injection of naive T cells prior to Listeria OVA infection to follow
responses. If possible, T cells with different features (WT and ARE-DEL) were co-injected to
prevent effects by individual differences. Mice were always age and sex matched.
For in vitro essays reporter constructs and other variations were tested in parallel in T cells
from different individuals. All critical experiments were either performed independently by
two researchers and yielded the same results, or they were performed by at least two
researchers in a team.

5. Blinding
Describe whether the investigators were blinded to
group allocation during data collection and/or analysis.

Mass spectrometry samples were number coded prior to analysis.
No further blinding was applied in this study, as internal controls were used in each
experiment to obtain unbiased data.

Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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6. Statistical parameters

n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.

A description of any assumptions or corrections, such as an adjustment for multiple comparisons
Test values indicating whether an effect is present
Provide confidence intervals or give results of significance tests (e.g. P values) as exact values whenever appropriate and with effect sizes noted.

A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.

`
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the
Methods section if additional space is needed).

Software

Policy information about availability of computer code

7. Software
Describe the software used to analyze the data in this
study.

Flow Cytometry data analysis was performed using FlowJo software (Tree Star, version 7.6.5
and version 10).
Mass spectrometry data analysis was performed with the MaxQuant computational platform,
1.5.0.25 (RNA pull down) or 1.6.0.13 (memory OTI T cells). The ‘proteingroups.txt’ table was
filtered for potential contaminants and reverse hits using Perseus 1.5.0.31 (RNA pull down) or
1.5.1.6 (memory OTI T cells).
RNA seq data were reanalysed for Reads per million mapped reads (RPM) and transformed as
log2-normalized counts using DESeq2.
Statistical analysis between groups was performed with GraphPad Prism 6, using the 2-tailed
Student t test when comparing 2 groups, or one-way ANOVA test with Dunnett correction
when comparing > 2 groups. P values <0.05 were considered statistically significant.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for
providing algorithms and software for publication provides further information on this topic.
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Materials and reagents

Policy information about availability of materials

8. Materials availability
Indicate whether there are restrictions on availability of
unique materials or if these materials are only available
for distribution by a third party.

No restrictions apply to the availability of materials.
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9. Antibodies

Mouse cells were labeled with:
anti-CD8 / 53-6.7 / 45-0081-82 / 4291993 / 1:400 / eBioscience
anti-CD4 / GK1.5 / 48-0041-82 / 4289896 / 1:400 / eBioscience
anti-CD45.1 / A20 / 110722 / B191340 / 1:400 / eBioscience
anti-CD45.2 / 104 / 109808 / B155231 / 1:400 / eBioscience
anti-Vβ5.1-5.2 / MR9-4 / 553189 / 66507 / 1:400 / BD Biosciences
anti-CD44 / IM7 / 25-0441-82 / E07565-1632 / 1:400 / eBioscience
anti-CD62L / MEL-14 / 104441 / B213054 / 1:400 / BioLegend
anti-CD127 / A7R34 / 45-1271-82 / E08358-1631 / 1:200 / eBioscience
anti-KLRG1 / MAFA (2F1) / 138416 / B196268 / 1:400 / BioLegend
anti-IFN-γ / XMG1.2 / 17-7311-82 / 4332526 / 1:300 / eBioscience
anti-TNF-α / MP6-XT22/ 12-7321-82 / E02144-1632 / 1:300 / eBioscience
Human T cells were labeled with:
anti-CD3 / UCHT1 / 737657 / 7973016 / 1:50 / Beckman Coulter
anti-CD4 / SK3 / 345769 / 80868 / 1:50 / BD Biosciences
anti-CD8 / SK1 / 345775 / 6229889 / 1:300 / BD Biosciences
Dead cells were excluded with 1ng/ml TO-PRO-3 iodide (T3605, Sigma-Aldrich), or Near-IR
(L10119, Life Technology / 1:800 dilution factor).
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Describe the antibodies used and how they were validated Flow Cytometry:
for use in the system under study (i.e. assay and species). Name / Clone name / Catalog no. / (most used) Lot no. / dilution factor / manufacturer

Western blot:
Name / Catalog no. / (most used) Lot no. / dilution factor / manufacturer
Primary antibodies:
rabbit anti-ZFP36L1 polyclonal antibody / ab42473 / GR33550-6 / 1:250 / Abcam
rabbit anti-ZFP36L2 polyclonal antibody / ab70775 / GR93627-6 / 1:250 / Abcam
mouse anti-RhoGDI monoclonal antibody / MAB9959 / 2017102001 / 1:1000 / Abnova
mouse anti-GAPDH monoclonal antibody / MAB374 / 2842113 / 1:500 / Millipore
rat pan-ZFP36 antibody / (M. Turner & J. McHugh unpublished data) / 1ug/ml
Secondary antibodies:
goat anti-rabbit-HRP / 4050-05 / 1:10000 / Southern Biotech
goat anti-mouse-HRP / 1031-05 / 1:10000 / Southern Biotech
goat anti-rat-HRP / 31470 / 1:10000 / Invitrogen
The specificity of anti-ZFP36L1 polyclonal and pan-ZFP36 family monoclonal antibodies was
assessed using transfected HEK 293T cells; the polyclonal antibody was also assessed using
ZFP36/ZFP36L1 ko mice (M. Turner & J. McHugh unpublished data). The anti-ZFP36L2
polyclonal antibody was verified by western blot analysis of ZFP36L2 ko T cells (see
supplemental Fig 7D).
RNA pull downs were validated with Western blot analysis.

10. Eukaryotic cell lines

`

a. State the source of each eukaryotic cell line used.

For virus production, PlatE cells (Morita et al., Gene therapy 2000. 7:1063-1066), received
from the lab for mouse and phoenix A cells for human T cells (ATCC® CRL-3213™) were used.

b. Describe the method of cell line authentication used.

Both cell lines yielded retrovirus and allowed for successful transduction of human and
mouse T cells.

c. Report whether the cell lines were tested for
mycoplasma contamination.

Cell lines are regularly tested for mycoplasma and were negative for more than 8 years.

d. If any of the cell lines used are listed in the database
of commonly misidentified cell lines maintained by
ICLAC, provide a scientific rationale for their use.

Cell lines are not listed

Animals and human research participants

11. Description of research animals
Provide all relevant details on animals and/or
animal-derived materials used in the study.

C57BL/6J, C57BL/6J.OT-I , C57BL/6J.OT-I IFN-g ARE-Del transgenic and Zfp36l2fl/fl CD4-cre
were used when 6 to 12 weeks old. Both male and female mice were included in this study.
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12. Description of human research participants
Describe the covariate-relevant population
characteristics of the human research participants.

Human T cells are derived from healthy blood donors that agreed to donate their blood to
research. The donation is anonymous, so no information on sex/age is available.
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